Patent intelligence · US
US 9051567
Methods for increasing efficacy of lipid formulated siRNA
Methods for increasing efficacy of lipid formulated siRNA
Patent details — US 9051567
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jun 9, 2015
- Expiration
- Jun 4, 2035
- Applicant
- Tekmira Pharmaceuticals Corporation
- Claims
- 25
- CPC classes
- A61K, A61K31/366, A61K31/567, A61K31/7088
Quick answer
US 9051567 (Methods for increasing efficacy of lipid formulated siRNA) is held by Tekmira Pharmaceuticals Corporation. Status: granted. Granted Jun 9, 2015. Expires Jun 4, 2035 (9 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Tekmira Pharmaceuticals Corporation
- Grant date
- Expiration
- Claims
- 25
- CPC classes
- A61K, A61K31/366, A61K31/567, A61K31/7088, A61K9/127, A61P
More from Tekmira Pharmaceuticals Corporation
Related pharmaceutical patents in our USPTO index.
-
US 12421228
Naphthyridine derivatives as PRC2 inhibitors
granted -
US 12421253
Tetrahydropyridopyrimidine pan-KRas inhibitors
granted -
US 12414911
Topical compositions and methods of use
granted -
US 12412764
Substrate-accommodating container
granted -
US 12398154
Azaquinazoline pan-KRas inhibitors
granted -
US 12383503
Adagrasib solid pharmaceutical compositions
granted -
US 12377101
Combination therapies
granted -
US 12371435
Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors
granted
Frequently asked questions
What is US patent 9051567?
US 9051567 (Methods for increasing efficacy of lipid formulated siRNA) is held by Tekmira Pharmaceuticals Corporation. Status: granted. Granted Jun 9, 2015. Expires Jun 4, 2035 (9 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 9051567?
Tekmira Pharmaceuticals Corporation is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 308 pharmaceutical patents for this assignee.
When does US 9051567 expire?
Our index shows an expiration date of Jun 4, 2035 (9 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.